Neuropeptide Y produces anxiety via Y2-type receptors.
In the present study, the effects of intracerebroventricular (ICV) NPY, [Leu31, Pro34]NPY and NPY13-36 have been evaluated with respect to anxiety in mice in the elevated plus maze. NPY had opposing effects on behavior, depending on the doses used. NPY decreased the normal preference for the closed arms of the maze at 0.7 nmol, indicating an anxiolytic effect; however, at 7 pmol NPY further increased the preference for the closed arm, indicating an anxiogenic effect. [Leu31, Pro34]NPY, a Y1-type receptor agonist, significantly reduced the preference for the closed arms at 70 pmol. NPY13-36, a Y2-type receptor agonist, significantly intensified the preference at 20 pmol. It has been demonstrated that NPY produces not only an anxiolytic effect via Y1-type receptors, but also an anxiogenic effect via Y2-type receptors. The time course of these NPY actions are quite different and the anxiogenic effect was observed only shortly after ICV NPY injection.
Nakajima
M
M
Second Department of Internal Medicine, Kobe University School of Medicine, Japan.
Inui
A
A
Asakawa
A
A
Momose
K
K
Ueno
N
N
Teranishi
A
A
Baba
S
S
Kasuga
M
M
D000818:Animals; D001007:Anxiety / Q000139:chemically induced* / Q000503:physiopathology*; D001921:Brain / Q000187:drug effects / Q000502:physiology; D007276:Injections, Intraventricular; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D009478:Neuropeptide Y / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology* / Q000502:physiology; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology; D017476:Receptors, Neuropeptide Y / Q000187:drug effects* / Q000502:physiology*
D009478:Neuropeptide Y; D010446:Peptide Fragments; D017476:Receptors, Neuropeptide Y; C062924:neuropeptide Y (13-36); C095889:neuropeptide Y2 receptor; C062259:neuropeptide Y, Leu(31)-Pro(34)-